Belite Bio has said the results of the DRAGON trial of its oral therapy for sight-robbing disorder Stargardt disease type 1 (STGD1), tinlarebant, could support an FDA filing. The San Diego biotech ...
The Bilt Mastercard is currently unavailable to new applicants. Bilt launched Bilt 2.0 Cards in February 2026, with existing cardmembers eligible to transition to the new card. The information and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results